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Summary
While tumors become addicted to oncogenes like Ras, the microenvironment in which tumor cells reside changes during
tumorigenesis; the cells are surrounded initially by normal tissue and later by tumor tissue. Hence, we asked if Ras exerts
its oncogenic effects through the same set of effectors during different stages of tumorigenesis. We now show in human
cells that the Ras effector pathways MAPK, RalGEF, and PI3K are required to initiate tumor growth. Conversely, activation
of the PI3K/AKT pathway replaced Ras once tumors formed, although other effectors were still activated independently
of Ras, presumably by factors provided upon the establishment of a tumor microenvironment. Thus, as tumorigenesis
progresses the addiction of cancers to their initiating oncogene is reduced to, at least in the case of Ras, the PI3K/
AKT pathway.S I G N I F I C A N C E
Tumorigenesis is a dynamic process, and we show that this translates at the molecular level to differential requirements of Ras
oncogene signaling during various stages of tumor growth. Since cancers are treated once they have been established, and Ras
signaling was reduced to activation of PI3K/AKT in established tumors, the PI3K/AKT pathway may be particularly important for the
treatment of Ras-driven human cancers. The reduction of oncogene addiction during the dynamic growth of the solid tumors
appeared to be due to activation of Ras effectors by the tumor environment. This environment even fostered the tumorigenic
proliferation of otherwise nonmalignant cells in what can be best described as parasitic growth, which may reflect the known
heterogeneity in the neoplastic fraction of human tumors.Introduction
The small GTPase Ras is commonly mutated in human can-
cers, often glycine12 to valine (G12V), to remain in the constitu-
tively active oncogenic GTP bound state (Bos, 1989). It has
long been appreciated that expression of this active version of
Ras promotes tumor initiation by activating at least three dif-
ferent effectors based on the work from many labs using Ras
effector binding mutants, dominant-negative and constitutively
active proteins downstream of Ras, and pharmacological inhib-
itors: Raf, PI3-kinase (PI3K), and RalGEFs (Shields et al., 2000;
Ulku and Der, 2003). Raf is a serine/threonine kinase that is
localized to the plasma membrane from the cytoplasm and ac-
tivated by GTP-Ras. Activated Raf proteins then initiate a MAP
kinase (MAPK) signal transduction cascade that leads to trans-
formed morphologies, anchorage-independent growth, and
angiogenesis (Morrison and Cutler, 1997; Shields et al., 2000).
The PI3K is also activated via interaction of the p85 regulatory
subunit with GTP-Ras, leading to the phosphorylation of phos-
phoinositides, creating multiple cascades that lead to changes
in cell morphology, as well as fostering angiogenesis and cell
survival (Luo et al., 2003). Lastly, RalGEFs are a family of five
guanine exchange factors (GEFs) that are activated via their
recruitment to the plasma membrane by GTP-Ras, where they
activate RalA and RalB, the former of which appears to be re-
quired in tumorigenesis (Feig, 2003; Lim et al., 2005).CANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEIt is well established that Ras promotes the initiation of tu-
morigenesis. However, patients are diagnosed and treated
once tumors have already been established, during what is
termed tumor maintenance. In this regard, mice harboring a
doxycycline (dox)-inducible oncogenic version of Ras grew tu-
mors (in the absence of the tumor suppressor INK4a) upon in-
gesting dox, but when these treatments were ceased the tu-
mors regressed (Chin et al., 1999). It was concluded that
tumors become “addicted” to oncogenic Ras, requiring this
protein to both initiate and maintain tumor growth (Chin et al.,
1999), as is the case for other oncogenes (Giuriato et al., 2004).
Despite the fact that oncogenic Ras expression is required
during tumor initiation and maintenance, the normal microenvi-
ronment for which a tumor initiates is vastly different from that
in which a tumor is maintained. In particular, the altered micro-
environment of the tumor can play a positive role in tumor
growth. The stroma of a tumor is aberrant, having appearances
of undergoing a wound healing response (Dvorak, 1986) in
which cell proliferation can be stimulated and tumor growth
enhanced (Mueller and Fusenig, 2004). Mast cells are recruited
to the tumor and then release metalloproteinases, which in turn
free growth and angiogenic factors trapped in the ECM to pro-
mote tumor growth and progression (Coussens and Werb,
2002). The vasculature can supply a host of survival- and
growth-promoting factors (Bergers and Benjamin, 2003). EvenR INC. DOI 10.1016/j.ccr.2005.10.014 381
A R T I C L Ethe hypoxic environment of tumors can activate the transcrip-
tion factor HIF-1α, and correspondingly a series of genes to
counter hypoxia that are advantageous to the tumor, including
those that foster angiogenesis, cell proliferation and survival,
and glycolysis, to name a few (Harris, 2002).
Given that the microenvironment in which tumor cells reside
changes as a tumor becomes established, we asked whether
Ras exerts its oncogenic effects through the same set of effec-
tors during tumor initiation and maintenance. However, any
one of the three major Ras effectors alone can promote tumor
initiation and hence presumably tumor maintenance of trans-
formed murine cells (Rangarajan et al., 2004) and, although
with different kinetics, also in rat mammary glands in vivo
(McFarlin and Gould, 2003; McFarlin et al., 2003). Indeed,
transformation and tumorigenesis are typically more lax in ro-
dent cells than in human cells (Lim and Counter, 2004; Rangar-
ajan and Weinberg, 2003). We therefore chose to focus our
studies on human cells. In this regard, expression of the SV40
viral oncoproteins T- and t-Ag and the mammalian protein
hTERT (the catalytic subunit of telomerase) in conjunction with
oncogenic (G12V) Ras (RasG12V) drives normal human cells
from a wide spectrum of cell types to a tumorigenic state (Hahn
et al., 1999; O’Hayer and Counter, 2005), providing a simplified
and defined system to explore Ras oncogenesis in human cells
(Hamad et al., 2002). Using this system, we replaced Ras with
different combinations of molecules that activate Ras effector
pathways to determine which signals were required to initiate
tumor growth and, by generating tumors with an inducible Ras
protein, which pathways maintained tumor growth once Ras
expression was silenced.
Results and discussion
Multiple Ras effectors are required to initiate tumor
growth of human cells in vivo
To explore the requirements of oncogenic Ras signaling during
the dynamic process of tumorigenesis, we sought to identify
the signals activated by oncogenic Ras that are required to
initiate versus maintain tumor growth of human cells. To first
identify the pathways required for tumor initiation, we replaced
oncogenic Ras with molecules that preferentially activate PI3K,
MAPK, or RalGEF pathways in primary human embryonic kid-
ney cells engineered to express T-Ag, t-Ag, and hTERT (termed
TtH cells). Since tumor growth of TtH cells was already shown
to minimally depend upon expression of the E37G mutant of
oncogenic Ras (Hamad et al., 2002), which primarily activates
RalGEFs (White et al., 1996), we tested whether activation of
the PI3K pathway, the MAPK pathway, or both cooperate with
RasG12V,E37G to initiate tumor growth. RasG12V,E37G was stably
coexpressed in TtH cells with either a control vector, an acti-
vated form of Raf-1 (Raf22W) to stimulate the MAPK pathway
(Stanton et al., 1989), an activated form of PI3K (p110-CAAX)
to stimulate the PI3K pathway (Rodriguez-Viciana et al., 1997),
or both Raf22W and p110-CAAX. As further controls, TtH
cells harboring vector alone or a vector encoding oncogenic
Ras were generated. The resultant six polyclonal cell lines were
confirmed to express the desired transgenes (Figure 1A) and
assayed for activation of the MAPK and PI3K pathways by
measuring the levels of phosphorylated ERK1 and 2 (ERK1/2)
and phosphorylated AKT, respectively. As expected, ERK1 and
ERK2 were specifically activated only in cells expressing382Raf22W, whereas AKT was weakly activated in all cells, appa-
rently due to the leaky nature of the RasG12V,E37G mutant, al-
though AKT was clearly the most phosphorylated in cells ex-
pressing p110-CAAX (Figure 1B).
The six cell lines were each injected subcutaneously into four
immunocompromised mice, and tumor growth was monitored
over time. Only cells in which all three Ras effector pathways
were activated were tumorigenic. Specifically, cells coexpress-
ing RasG12V,E37G, Raf22W, and p110-CAAX were the most
aggressive followed by cells coexpressing RasG12V,E37G and
Raf22W (Figure 1D), in which PI3K was weakly activated by
the RasG12V,E37G protein (Figure 1B). PI3K activation was shown
to be required in the latter cells, as diminishing AKT activa-
tion by expression of PTEN, a negative regulator of this path-
way (Vivanco and Sawyers, 2002), abolished the tumorigenic
growth of these cells (Figures 1C and 1D). Since robust activa-
tion of any two of the RalGEF, PI3K, or MAPK pathways failed
to initiate tumor growth (Figure 1D and Hamad et al., 2002), we
conclude that these three effectors are minimally required to
initiate human tumor cell growth of TtH cells. In agreement,
multiple Ras effectors have been reported to drive a variety of
human cells expressing hTERT, T-Ag, and t-Ag to a tumorigenic
state (Rangarajan et al., 2004).
Oncogene addiction in human tumor cells
To determine if Ras was required during tumor maintenance
in human cells, a 4-hydroxytamoxifen (4-OHT)-inducible ER:
RasG12V fusion protein (Dajee et al., 2002) comprised of a mu-
tant form of the estrogen receptor ligand binding domain and
oncogenic Ras was expressed in TtH cells. As a negative con-
trol, TtH cells were stably infected with a control retrovirus, and
as a positive control, the cells were stably infected with a ret-
rovirus encoding RasG12V. Like vector control cells, in the ab-
sence of the 4-OHT the fusion protein was undetectable and
did not stimulate the MAPK, PI3K, or RalGEF pathways, as
measured by an increase in AKT and ERK1/2 phosphorylation
and the level of GTP bound RalA, respectively (Figures 2A and
3A). This inability to activate Ras effectors was reflected in as-
says of Ras oncogenesis. In the absence of 4-OHT, ER:
RasG12V-TtH cells behaved like vector control cells and failed
to grow in soft agar (Figure 2B and data not shown) or form
tumors in mice (Figure 2C). Conversely, binding of 4-OHT by
the ER portion of the fusion protein relieved this inhibition, re-
sulting in detectable ER:RasG12V protein that behaved like pos-
itive control RasG12V, activating Ras effectors (Figures 2A and
3A) and promoting anchorage-independent (Figure 2B and
data not shown) and tumorigenic growth (Figure 2C). We next
addressed whether Ras was required for tumor maintenance,
and here we show that inducible inhibition of ER:RasG12V after
tumors had formed by halting 4-OHT treatments led to tumor
regression (Figure 2C). Thus, as in murine models (Chin et al.,
1999; Tarutani et al., 2003), human cells become addicted to
oncogenic Ras for maintenance of tumorigenic growth.
Activation of the PI3K pathway maintains tumor
growth in the absence of oncogenic Ras
We next tested which Ras effector pathway(s) need to be acti-
vated to overcome the tumor regression observed upon sup-
pressing ER:RasG12V expression in established tumors. Two in-
dependent approaches were used to preferentially activate one
arm of Ras oncogenic signaling in ER:RasG12V TtH cells: acti-CANCER CELL : NOVEMBER 2005
A R T I C L EFigure 1. Tumor initiation is mediated by multiple Ras effectors
A: Detection of ectopic Raf22W and oncogenic Ras by immunoblot, and p110-CAAX by RT-PCR in TtH cells expressing the indicated transgenes. Total
actin and GAPDH serve as loading controls.
B: Detection of phosphorylated Akt (P-Akt) and ERK1/2 (P-ERK), as a measure of PI3K and MAPK activation, in TtH cells expressing the indicated transgenes.
Total AKT and ERK1/2 serve as loading controls.
C: Detection of PTEN, and as a measure of PI3K and MAPK activation, phosphorylated Akt (P-Akt) and ERK1/2 (P-ERK) in TtH cells expressing the indi-
cated transgenes.
D: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with TtH cells expressing the following:
RasG12V (white squares) or RasG12V,E37G in addition to either vector (white diamonds), p110-CAAX (black squares), Raf22W (black triangles), p110-CAAX
+ Raf22W (black circles), or Raf22W + PTEN (white circles).levels, respectively (Figures 3A and 3D), and all lines grew in a
Figure 2. Oncogene addiction in human cells
A: Detection of ectopic ER:RasG12V and RasG12V by immunoblot, as well as the appropriate activation of the PI3K and MAPK pathways, as visualized by
an increase in phosphorylated Akt (P-Akt) and ERK1/2 (P-ERK1/2), in TtH cells expressing the indicated transgenes in the absence (−) or presence (+) of
4-OHT. Total Akt and ERK1/2 serve as loading controls.
B: Representative image of anchorage-independent growth 3 weeks after 105 ER:RasG12V-TtH cells expressing no transgene (vector) were seeded in
triplicate in soft agar in the absence (−) or presence (+) of 4-OHT. Below: average number of colonies and standard deviation, expressed as a percent of
ER:RasG12V colony growth in the presence of 4-OHT.
C: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with TtH cells expressing vector (white
diamonds) or ER:RasG12V in the presence of 4-OHT until day 28 (black triangles, arrow) or until the tumors reached maximum volume (black squares).
ER:Ras expression until a tumor mass was clearly visiblevated effectors (Figure 3A) or Ras effector mutants (Figure 3D).
Specifically, RasG12V,T35S or Raf22W to activate the MAPK
pathway (Stanton et al., 1989; White et al., 1995), RasG12V,Y40C
or p110-CAAX to activate the PI3K pathway (Rodriguez-Vici-
ana et al., 1997), or lastly, RasG12V,E37G or Rlf-CAAX to activate
the RalGEF pathway (White et al., 1996; Wolthuis et al., 1997)
was stably expressed in ER:RasG12V-TtH cells, as assessed by
immunoblot analysis (Figures 3A and 3D). In the presence of
4-OHT to activate ER:RasG12V, all six cell lines had activated
MAPK, PI3K, and RalGEF pathways, as measured by an in-
crease in ERK1/2 and AKT phosphorylation, and RalA-GTPCANCER CELL : NOVEMBER 2005soft agar, a measure of oncogenic Ras activity (Figures 3B and
3E). In the absence of 4-OHT, the targeted pathways still re-
mained activated (Figures 3A and 3D), but consistent with pre-
vious results (Hamad et al., 2002), only cells with an activated
RalGEF pathway could still grow in soft agar (Figures 3B and
3E). Thus, specific Ras effector pathways can be selectively
activated in a background in which Ras expression can be con-
trolled, providing a means to test which Ras effector pathways
maintain tumor growth in the absence of oncogenic Ras.
These six cell lines and one vector control cell line were each
injected into four mice given daily doses of 4-OHT to induce
G12V383
A R T I C L EFigure 3. Reduction in the dependence upon cell-autonomous oncogenic signaling to activation of PI3K during tumor maintenance
A and D: Detection where indicated of ectopic ER:RasG12V, Raf22W, Rlf-CAAX, and Ras effector mutants by immunoblot, p110-CAAX by RT-PCR, and the
appropriate activation of the MAPK, PI3K, and RalA pathways, as visualized by an increase in phosphorylated Akt (P-Akt), ERK1/2 (P-ERK1/2), or the level
of RalA-GTP, respectively, in ER:RasG12V-TtH cells expressing the indicated transgenes in the absence (−) or presence (+) of 4-OHT. Total Akt, ERK1/2, RalA,
and GAPDH serve as loading controls. B and E: Representative image of anchorage-independent growth 3 weeks after 105 ER:RasG12V-TtH cells expressing
the indicated transgene were seeded in triplicate in soft agar in the absence (−) or presence (+) of 4-OHT. Below: average number of colonies ± standard
deviation, expressed as a percent of colony growth of ER:RasG12V-TtH cells infected with an empty vector. C: Average and standard deviation of tumor
volume (mm3) from groups of four mice versus time (days) injected with ER:RasG12V-TtH cells expressing vector (white diamonds), Rlf-CAAX (black circles),
p110-CAAX (red squares), or Raf22W (black triangles) after 4-OHT treatments were halted (arrow) once tumors were established, or ER:RasG12V-TtH cells
expressing p110-CAAX in the absence of 4-OHT throughout the entire experiment (white squares). F: Average and standard deviation of tumor volume
(mm3) from groups of four mice versus time (days) injected with ER:RasG12V TtH cells expressing vector (white diamonds), RasG12V,E37G (black circles),
RasG12V,Y40C (red squares), or RasG12V,T35S (black triangles) after 4-OHT treatments were halted (arrow) once tumors were established.(a diameter of 0.7 cm, approximately the size of a pea). At this
point, 4-OHT treatments were ceased to terminate ER:RasG12V
signaling, and tumor growth was monitored for another w25
days, or until tumors reach a maximum volume of w1500
mm3. Within 2 days of halting 4-OHT treatments, tumors in
which either the MAPK (RasG12V,T35S or Raf22W) or RalGEF
(RasG12V,E37G or Rlf-CAAX) pathways were constitutively acti-
vated stopped growing and in some mice actually regressed
akin to vector control tumors (Figures 3C and 3F). Conversely,
tumors composed of cells expressing RasG12V,Y40C or p110-
CAAX that preferentially activated PI3K, but not the RalGEF
and MAPK pathways (Figures 3A and 3D), continued to grow
in the absence of oncogenic Ras (Figures 3C and 3F). Activa-
tion of the PI3K pathway was not, however, alone sufficient to
promote tumor growth, as TtH cells coexpressing ER:RasG12V
and p110-CAAX injected into four mice in the absence of 4-OHT
were not tumorigenic (Figure 3C). Additionally, ER:RasG12V-TtH
cells expressing p110-CAAX did not acquire mutations that384allowed them to grow upon suppressing ER:RasG12V. When
such cells were isolated from tumors established after 4-OHT
had been removed, recultured under drug selection to kill con-
taminating murine cells, and injected back into four mice in the
absence of 4-OHT treatments, no tumors were detected (data
not shown). Lastly, these results were reproducible, not only
because activation of the PI3K by two different means main-
tained tumor growth in the absence of ER:RasG12V expression
(Figures 3C and 3F), but also because expression of T-Ag,
t-Ag, hTERT, ER:RasG12V, and the described activated versions
of the three Ras effectors in HEK cells isolated from a com-
pletely different donor resulted in identical results, namely that
only activation of the PI3K pathway could sustain tumor growth
in the absence of ER:RasG12V (data not shown). We conclude
that, while Ras-induced tumor initiation of TtH cells minimally
requires the activation of the RalGEF, PI3K, and MAPK path-
ways (Figure 1D), once a tumor is formed the requirement ofCANCER CELL : NOVEMBER 2005
A R T I C L ERas oncogenic signaling can be reduced to activation of the
PI3K pathway (Figure 3).
Inhibition of the PI3K pathway inhibits
tumor maintenance
If activation of the PI3K pathway maintained tumor growth in
the absence of oncogenic Ras, we reasoned that blocking the
PI3K pathway in established tumors should inhibit tumor main-
tenance in the presence of Ras. Akin to our approach to induci-
bly regulate Ras expression, we infected RasG12V-transformed
TtH cells with a retrovirus encoding 4-OHT-inducible PTEN:ER,
generated by fusing the mutant form of the estrogen receptor
ligand binding domain to PTEN, a negative regulator of the
PI3K pathway (Vivanco and Sawyers, 2002). In the absence
of the 4-OHT, this fusion protein was nearly undetectable by
immunoblot and unable to inhibit the PI3K pathway. Con-
versely, activation of PI3K by RasG12V was specifically inhibited
in the presence of 4-OHT, as phosphorylation of Akt, but not
ERK1/2, was lost (Figure 4A).
Having established that PI3K activity could be inducibly in-
hibited, we injected the resultant cells into ten mice to establish
tumors, at which point six mice were treated with 4-OHT to
induce PTEN:ER expression and inhibit the PI3K pathway, and
as a control, four were left untreated. Tumors in the untreated
mice continued to grow unabated, reaching maximum tumor
volume 12 days later, whereas tumor growth was greatly inhib-
ited in mice treated with 4-OHT (Figure 4B), resulting in visibly
stunted tumor growth (Figure 4C). When tumors eventually did
arise in the presence of 4-OHT, in every case (tumors 3–6, Fig-
ure 4D) there was a selection for cells that overcame 4-OHT
induction of PTEN:ER expression and restored AKT activation
to levels equivalent to those observed in tumors grown in the
absence of 4-OHT (Figure 4D, tumors 1 and 2). Thus, contin-
ued tumor growth of established tumors was halted by inhibit-
ing the PI3K pathway.Figure 4. PI3K activation is required during tumor maintenance
A: Detection of PTEN:ER, or as a measure of activated PI3K or MAPK pathways, phosphorylated Akt (P-Akt) or ERK1/2 (P-ERK1/2), respectively, by immu-
noblot in the absence (−) or presence (+) of 4-OHT in RasG12V-TtH cells coexpressing PTEN:ER. Total ERK1/2 and Akt serve as loading controls.
B: Average and standard deviation of tumor volume (mm3) from groups of ten mice versus time (days) injected with RasG12V-TtH cells expressing 4-OHT-
inducible PTEN:ER either in the continued absence of 4-OHT (white squares) or upon treatments of 4-OHT to induce PTEN:ER expression once tumors
reached a diameter of 0.7 cm (red squares). Day 0 (arrow): the point when tumors reached a diameter of 0.7 cm (and 4-OHT treatments were begun).
C: Representative tumors observed at the same time in mice (arrow: approximate site of injection) or when resected from one of the mice injected with
RasG12V-TtH cells expressing PTEN:ER either in the absence of 4-OHT (−4OHT) or after 4-OHT treatments (+4OHT) were started at a tumor diameter of 0.7
cm. Tumors were analyzed once control (−4OHT or −dox) tumors reached maximum volume.
D: Detection of PTEN:ER and phosphorylated Akt (P-AKT) and ERK1/2 (P-ERK1/2) in RasG12V-TtH cells expressing 4-OHT-inducible PTEN:ER in culture before
implanting into mice in the absence (−) or presence (+) of 4-OHT, or from cells purified from two resultant tumors grown in the absence of 4-OHT (tumors
1 and 2) or from four tumors (tumors 3–6) that eventually overcame the inhibitory effects of 4-OHT. Endogenous PTEN serves as a loading control.CANCER CELL : NOVEMBER 2005PI3K activation is required to maintain growth
of cells in an established tumor
It is possible that, in the absence of 4-OHT, ER:RasG12V weakly
activated effectors to levels that were undetectable by measur-
ing AKT and ERK1/2 phosphorylation and RalA-GTP levels,
which in turn cooperated with p110-CAAX to foster tumor
growth once 4-OHT treatments were halted. To definitively test
if autocrine activation of the PI3K pathway is indeed alone suf-
ficient to support tumor growth in the absence of Ras, and
does not rely on possible weak activation of other Ras effec-
tors by low levels of ER:RasG12V, we tested whether nonmalig-
nant TtH cells expressing p110-CAAX (but not ER:RasG12V)
were tumorigenic once tumor growth was initiated by com-
pletely different RasG12V-expressing TtH cells (Figure 5A). Four
mice were injected with a mixture of TtH cells stably expressing
either RasG12V (to establish a tumor) or p110-CAAX (and the
visual marker LacZ to identify these cells). As a control, we
similarly injected four mice each with a mixture of TtH cells
expressing RasG12V and TtH cells coexpressing LacZ and
either an empty vector, Raf22W, to activate the MAPK path-
way, or Rlf-CAAX to activate the RalGEF pathway.
The mixture of RasG12V cells and p110-CAAX cells led to tu-
mors that grew faster than any of the other combinations
tested (Figure 5C). Moreover, when two tumors were excised
and treated with 5-bromo-4-chloro-3-indolyl-β-D-galactopy-
ranoside (X-gal) to stain LacZ-expressing p110-CAAX cells
blue, the tumors exhibited prominent blue staining (Figure 5B).
To ascertain more accurately the contribution of p110-CAAX
cells in the tumor, the two remaining tumors were resected,
and individual cultures were established in the presence of
drug selection to kill contaminating murine cells and enrich for
the injected human cells. Upon treatment of the resultant cul-
tures with X-gal, almost one-quarter of the cells stained
strongly for LacZ, with many more being weakly positive (Fig-
ure 5B). This number far exceeds the amount injected, indicat-385
A R T I C L EFigure 5. Activation of PI3K maintains tumor growth in established tumors
A: Diagram of mixing experiment involving RasG12V-TtH cells (malignant) to establish a tumor with LacZ-positive TtH cells expressing different activated
versions of Ras effectors (nonmalignant).
B: Four mice were injected with a mixture of RasG12V-TtH cells and LacZ-positive TtH cells expressing the indicated transgenes, after which tumors were
resected when they reached maximum volume, and two were immediately treated with X-gal (representative tumor, top panel) and two were adapted
to grow in culture and then treated with X-gal to visualize LacZ-positive cells (representative culture, bottom panel).
C: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with a mixture of vector and LacZ-positive
TtH cells (white squares) or a mixture of RasG12V-TtH cells and LacZ-positive TtH cells expressing no transgene (vector, white diamonds), Raf22W (blue
triangles), Rlf-CAAX (blue circles), or p110-CAAX (blue diamonds) or injected with LacZ-positive TtH cells expressing p110-CAAX that were purified from two
different tumors established when these cells were originally mixed with RasG12V-TtH cells (white circles and triangles).ing that the p110-CAAX TtH cells proliferated in what could
best be described as a parasitic fashion, greatly contributing to
the malignant mass of the tumors while on their own remaining
unable to initiate tumor growth.
The p110-CAAX cells in the tumors did not acquire any addi-
tional changes to allow them to grow in this malignant fashion.
Neither the original p110-CAAX/LacZ cells nor those isolated
from two different tumors (with Ras-transformed cells removed
by drug selection) and reinjected into four mice each formed
tumors (Figure 5C). Similarly, neither vector control nor those
cells with a constitutively active MAPK or RalGEF pathway
contributed significantly to the tumors (Figure 5B). Thus, in the
complete absence of oncogenic Ras, activation of the PI3K
pathway, and not other Ras effectors, sustains tumor growth.
Ras effector activation in established tumors
The reduced requirement for Ras oncogenic signaling during
tumor maintenance could be due either to a frank lack of any
need for MAPK and RalGEF activity, or to Ras-independent
stimulation of these pathways once a tumor is established. To
address these two possibilities, we first assayed whether tu-
mors maintained by p110-CAAX had activated the MAPK and
RalGEF pathways in vivo, despite lacking ER:RasG12V expres-
sion and not activating these pathways in culture. Three dif-
ferent tumors derived from ER:RasG12V TtH cells expressing
p110-CAAX were resected from mice w25 days after 4-OHT
treatments were halted, well beyond the point when ER:
RasG12V expression was extinguished in culture after 4-OHT
removal, and assayed for ER:RasG12V expression and activa-
tion of PI3K, MAPK, and RalGEF pathways. As expected, ER:
RasG12V was not detected in these tumors, as they were grown
in the absence of 4-OHT, and the PI3K pathway was activated
(Akt was phosphorylated), owing to ectopic p110-CAAX ex-
pression. However, even though ER:RasG12V was not ex-
pressed in these tumors, and these cells did not activate the
MAPK or RalGEF pathways in the absence of 4-OHT in culture,386in the tumors ERK1 and ERK2 were phosphorylated, a mea-
sure of MAPK activation, and the levels of RalA-GTP were ele-
vated, a measure of RalGEF activation (Figure 6A). Thus, the
remaining Ras effector pathways were activated in tumors
maintained by PI3K activity in the absence of oncogenic Ras
expression.
We next addressed whether this activation of MAPK and Ral-
GEF was important for tumor maintenance in the absence of
oncogenic Ras expression. In the case of the MAPK pathway,
RasG12V-transformed TtH cells were infected with a retrovirus
encoding 4-OHT-inducible MEKDN:ER that we generated by
fusing the mutant form of the estrogen receptor ligand binding
domain to the K97-M dominant-negative (DN) version of MEK1,
which is well established to inhibit the MAPK pathway (Man-
sour et al., 1994). In the absence of 4-OHT, this fusion protein
was modestly expressed, but not at a level to robustly inhibit
the MAPK pathway. In the presence of 4-OHT, the protein was
abundantly expressed and clearly able to specifically inhibit ac-
tivation of MAPK pathway by RasG12V, as ERK1/2 phosphoryla-
tion was abolished without affecting the level of AKT phosphor-
ylation (Figure 6B). The resultant cells were injected into eight
mice to establish tumors, after which half the mice were treated
with 4-OHT to induce MEKDN:ER expression and inhibit the
MAPK pathway, and as a control, half were left untreated. Tu-
mors in untreated mice continued to grow unabated, reaching
maximum tumor volume 10 days later, whereas tumor growth
was inhibited in mice treated with 4-OHT (Figure 6E), resulting
in visibly stunted tumor growth (Figure 6D).
In the case of the RalGEF pathway, RalA shRNA has been
shown to inhibit RalGEF-induced transformation, and in a spe-
cific manner, as this effect was rescued by expression of a
siRNA-resistant RalA protein (Lim et al., 2005). To generate an
inducible RalA shRNA, RasG12V-transformed TtH cells were en-
gineered to express the TET repressor protein, which can be
inhibited by the molecule dox. The cells were then infected
with a retrovirus encoding RalA shRNA downstream of the TETCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 6. A role of MAPK and RalGEF pathways
in tumor maintenance
A: Cultured ER:RasG12V-TtH cells expressing p110-
CAAX in the absence (−) or presence (+) of
4-OHT or the resultant tumors derived from these
cells once maximum tumor volumes were
reached, after 4-OHT treatments were halted,
were immunoblotted to detect ER:RasG12V,
phosphorylated AKT (P-Akt), or ERK1/2 (P-ERK1/2)
and RalA-GTP as measures of activation of the
PI3K, MAPK, and RalGEF pathways, respectively.
B: Detection of MEKDN:ER or phosphorylated AKT
(P-Akt) or ERK1/2 (P-ERK1/2) as measures of acti-
vation of the PI3K or MAPK pathways, respec-
tively, by immunoblot in RasG12V-TtH cells ex-
pressing 4-OHT-inducible MEKDN:ER to inhibit the
MAPK pathway or a vector control in the ab-
sence (−) or presence (+) of 4-OHT. Total ERK1/2
and Akt serve as loading controls.
C: Detection of endogenous levels of RalA by
immunoblot in RasG12V-TtH cells stably express-
ing dox-inducible RalA shRNA to inhibit the Ral-
GEF pathway or a scramble control in the pres-
ence of increasing concentrations of dox.
D and E: Representative tumors in mice (arrow:
approximate site of injection) or when resected
from one of four mice injected with RasG12V-TtH
cells containing 4-OHT-inducible MEKDN:ER either
in the absence of the activating agent (−4OHT,
white squares) or after 4-OHT treatments were
started (+4OHT, blue squares) at a tumor diame-
ter of 0.7 cm. All tumors were analyzed once
control (−4OHT) tumors reached maximum
volume.
F and G: Average and standard deviation of tu-
mor volume (mm3) from groups of eight mice
versus time (days) injected with RasG12V-TtH cells
containing dox-inducible RalA shRNA either in
the continued absence of the activating agent
(−dox, white squares) or upon treatments with
dox once tumors reached a diameter of 0.7 cm
(+dox, green squares). Day 0 (arrow): the point
when tumors reached a diameter of 0.7 cm and
4-OHT or dox treatments were initiated to inhibit
the MAPK or RalGEF pathway, respectively.operator and, when exposed to dox, were shown to have a
dose-dependant decrease in endogenous RalA protein levels,
as assessed by immunoblot (Figure 6C). These cells were then
injected into eight mice, allowed to form tumors, and then
either treated with dox to induce RalA shRNA or left untreated.
In this case, inhibition of the RalGEF pathway actually caused
tumor regression in some mice (Figure 6G), and resected tu-
mors were substantially reduced in their mass (Figure 6F).
Thus, activation of the MAPK and RalGEF pathways is still re-
quired for tumor maintenance, although this activation is inde-
pendent of oncogenic Ras.
The PI3K/AKT pathway prevents apoptosis
during tumor maintenance
While the MAPK and RalGEF pathways can be activated in the
absence of oncogenic Ras once a tumor is established, PI3K
was the only effector that still had to be activated in an autono-
mous fashion in tumor cells. We therefore addressed what
function of oncogenic Ras was so critical that it could not be
lost during tumor maintenance. As a starting point, we com-
pared the effects of the loss of oncogenic Ras in the presenceCANCER CELL : NOVEMBER 2005and absence of p110-CAAX on tumor histology. Twelve mice
were injected with ER:RasG12V-TtH cells expressing either
p110-CAAX or no transgene (vector). Tumors were allowed to
reach a diameter of 0.7 cm in the presence of 4-OHT, after
which these treatments were ceased, and 3, 5, 9, 12, 15, and
20 days later one mouse from each of the two treatment
groups was photographed or a tumor was removed and ana-
lyzed for apoptosis (TUNEL-positive), cell proliferation (Ki67-
positive), and/or general histology (H&E staining). In vector
control cells, there was a clear increase in TUNEL-positive (Fig-
ure 7A) cells and a decrease in Ki67-positive (Figure 7B) cells
at day 5, followed by a dramatic collapse of tumor cellular ar-
chitecture and appearance of hemorrhagic foci, nuclear and
cytoplasmic debris at day 9 (Figure 7C), the near complete loss
of overall tumor structure at day 15 (Figure 7D), and the ab-
sence of a visible tumor mass at day 20 (Figure 7E). During the
same time course, p110-CAAX-expressing tumors continued
to grow and did not show these profound changes in tumor
histology (Figures 7A–7E).
As cellular apoptosis preceded the demise of vector control
tumors upon silencing ER:RasG12V expression, we speculated387
A R T I C L EFigure 7. The Akt pathway prevents apoptosis during tumor maintenance
A–E: Mice were injected with ER:RasG12V-TtH cells expressing vector or p110-CAAX, tumors were established, then 4-OHT treatments were halted; at the
indicated times afterwards one tumor from each treatment group was sectioned and H&E stained and assayed for TUNEL-positive (dark brown) cells (A);
assayed for Ki67-positive (dark brown) cells (B); or H&E-stained (V, viable regions; N, necrotic regions) (C and D). E: Mice harboring tumors derived from
ER:RasG12V-TtH cells expressing vector or p110-CAAX were photographed 20 days after 4-OHT treatments were halted (arrow: approximate site of injection).
F: Detection of ectopic myr-Akt, RacQ61L, ER:RasG12V, and endogenous PTEN by immunoblot, or the appropriate activation of the PI3K pathway, as
visualized by an increase in phosphorylated Akt (P-Akt), in TtH cells expressing ER:RasG12V and myr-Akt, RacQ61L, a vector encoding a siRNA specific for
PTEN (PTEN siRNA), or the corresponding scrambled sequence (scram) in the presence (+) or absence (−) of 4-OHT. Akt serves as a loading control.
*Nonspecific band.
G: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with ER:RasG12V-TtH cells expressing myr-
Akt (blue squares), RacQ61L (green circles), PTEN siRNA (red triangles), or scrambled control (white diamonds) after 4-OHT treatments were halted (arrow).that the effects of p110-CAAX might be related to promoting
cell survival. In agreement with this hypothesis, we show that
of two well-established downstream targets of PI3K, the pro-
growth and survival protein AKT (Vivanco and Sawyers, 2002),
but not Rac, a GTPase that affects the actin cytoskeleton (Bur-
ridge and Wennerberg, 2004), maintained tumor growth in the
absence of Ras. Specifically, a constitutively active version of
AKT (myr-AKT [Kulik et al., 1997]) or Rac (RacQ61L [Singh et al.,
2004]) was stably expressed in the ER:RasG12V-TtH cells (Fig-
ure 7F), and the resultant cell lines were injected into four mice
each treated daily with 4-OHT until tumors were established,
after which time these treatments were stopped to terminate
the ER:RasG12V signaling. Cells expressing myr-AKT continued
to grow in the absence of oncogenic Ras, whereas those ex-
pressing RacQ61L regressed (Figure 7G).
The PI3K pathway is negatively regulated by the tumor sup-
pressor PTEN, and PTEN expression is lost in many types of388cancer cells, leading to AKT activation (Vivanco and Sawyers,
2002). Thus, as a means to activate the PI3K pathway in a
more physiological way, we tested whether downregulation of
PTEN could maintain tumor growth in the absence of RasG12V.
ER:RasG12V-TtH cells were stably infected with a retrovirus en-
coding a PTEN shRNA, which led to a decrease in PTEN pro-
tein levels and activation of AKT in the absence of ER:RasG12V
(Figure 7F). The resulting population injected into four mice
readily formed tumors in mice that continued to grow unabated
when oncogenic Ras signaling was silenced by halting 4-OHT
treatments (Figure 7G). Conversely, tumors derived from con-
trol cells expressing a scrambled version of the shRNA that
failed to inhibit PTEN expression (Figure 7F) regressed upon
halting 4-OHT treatments (Figure 7G). These effects were lim-
ited to tumor maintenance, as ER:RasG12V-TtH cells expressing
either PTEN shRNA or myr-AKT were not tumorigenic in the
absence of 4-OHT (data not shown). We surmise from theseCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 8. Activation of PI3K maintains tumor growth in the absence of oncogenic Ras in human cancer cell lines
A: Detection of endogenous K-Ras knockdown by immunoblot in the human CAPAN-1 (pancreatic) and SW480 (colon) cancer cell lines harboring
dox-inducible shRNA specific for the endogenous oncogenic (G12V) K-Ras allele in the presence of increasing levels of dox. Total actin serves as a
loading control.
B: Rescue of K-RasG12V shRNA. Representative image of anchorage-independent growth 3 weeks after 105 CAPAN-1 cells expressing control vector or
K-RasG12V shRNA (noninducible) and either a control vector or one encoding siRNA-resistant K-RasG12V were seeded in triplicate in soft agar.
C: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with SW480 or CAPAN-1 cells constitutively
expressing both K-RasG12V shRNA and siRNA-resistant K-RasG12V (black squares or black triangles, respectively), or SW480 or CAPAN-1 cells expressing dox-
inducible K-RasG12V shRNA and p110-CAAX in the continued presence of dox (white squares or white triangles, respectively).
D: Average and standard deviation of tumor volume (mm3) from groups of four mice versus time (days) injected with CAPAN-1 cells expressing dox-
inducible K-RasG12V shRNA and either a control vector (white triangles) or one encoding p110-CAAX (black triangles) or SW480 cells expressing dox-
inducible K-RasG12V shRNA and either a control vector (white squares) or one encoding p110-CAAX (black squares) after dox treatments were initiated
(arrow).
E: Representative tumors in mice (top, arrow, location of injection) and when resected (bottom) after the described cells were injected in mice treated
with dox once tumors were established to inhibit the expression of the K-RasG12V allele. Tumors were viewed 36 days after dox treatments were begun.gain- and loss-of-function experiments that, once tumor
growth has been initiated, one of the main functions of onco-
genic Ras is to protect neoplastic cells from an apoptotic fate
by activation of the AKT pathway.
Activation of PI3K is required to maintain growth of
human cancer cell lines in the absence of oncogenic Ras
While we demonstrate using multiple assays that genetically
engineered human tumor cells depend upon PI3K activation
for tumor maintenance, we wished to address if the same
holds true in actual cancer cell lines isolated from patients
diagnosed with cancer in which Ras mutations are present.
Moreover, our studies were performed with H-Ras, whereas
most tumors have K-Ras mutations (Bos, 1989), and H- and
K-Ras can activate PI3K pathway to different extents (Yan et
al., 1998). We therefore introduced a dox-inducible shRNA spe-
cific for the endogenous oncogenic G12V allele of K-Ras (and
the TET repressor protein) into CAPAN-1 and SW480 cells, twoCANCER CELL : NOVEMBER 2005cell lines derived from completely different human cancers that
are known to express this mutant allele (Brummelkamp et al.,
2002; Ikehara et al., 2005), and showed by immunoblot that
addition of dox to the resultant cell lines led to a dose-depen-
dant decrease in endogenous K-Ras protein levels (Figure 8A).
The ability of this shRNA sequence to suppress oncogenic Ras
expression was reflected in assays of Ras oncogenesis, as
CAPAN-1 cells engineered to constitutively express the de-
scribed K-RasG12V shRNA (and an empty vector) failed to grow
in soft agar. Coexpression of a siRNA-resistant K-RasG12V pro-
tein in these cells restored soft agar growth to the level of vec-
tor control cells lacking any shRNA sequence (Figure 8B), indi-
cating that the effects of the shRNA were a consequence of
knocking down K-RasG12V expression. Similar observations
were found in assays of tumor growth. Specifically, tumor initia-
tion of CAPAN-1 and SW480 cells expressing dox-inducible
shRNA (and p110-CAAX; see below) in the presence of con-
stant dox treatments was greatly retarded. Again, this reduc-389
A R T I C L Etion in tumor growth was rescued in both cell lines in which the
constitutive knockdown of K-RasG12V was complemented by
expression of a siRNA-resistant K-RasG12V protein (Figure 8C).
Thus, we demonstrate that endogenous K-RasG12V can be spe-
cifically knocked down in two human cancer cell lines, resulting
in a reduction of Ras-mediated transformation and tumori-
genesis.
To next test if activation of the PI3K pathway could rescue
the loss of Ras function during tumor maintenance, p110-
CAAX or a control vector was introduced into the two cell lines
engineered to express dox-inducible K-RasG12V shRNA. The
resultant four populations were then each injected into four
mice in the absence of dox to allow K-RasG12V expression and
establish tumors. Upon initiation of dox treatments to knock
down K-RasG12V expression, vector control cells began to re-
gress, whereas those tumors expressing p110-CAAX contin-
ued to grow (Figure 8D), resulting in a clearly visible difference
in the tumor size between vector- and p110-CAAX-expressing
cells (Figure 8E). Activation of the PI3K pathway was not, how-
ever, alone sufficient to promote tumor growth in the absence
of RasG12V. Tumor initiation was greatly reduced or abolished
in the two cell lines harboring dox-inducible K-RasG12V shRNA
and p110-CAAX when injected into mice in the presence of
dox (to constitutively inhibit K-RasG12V expression), and in the
cases where tumors masses were detected, the tumors grew
extremely poorly (Figure 8C). Thus, activation of the PI3K path-
way maintained the tumorigenic growth of not only engineered
tumor cells in the absence of Ras, but also human cancer cell
lines.
Reduction in the requirements of oncogenic Ras
during tumorigenesis
Tumorigenesis is a dynamic process, and hence we addressed
whether Ras must activate the same signaling pathways during
tumor initiation as during tumor maintenance. We now demon-
strate that, while multiple arms of oncogenic Ras signaling are
required for tumor initiation, oncogenic activation of the down-
stream PI3K/AKT pathway is sufficient for tumor maintenance,
as (1) PI3K or AKT activation maintained tumor growth upon
loss of ER:RasG12V expression even though these molecules
did not activate other Ras effectors; (2) inducible expression of
PTEN stopped continued tumor growth of established tumors;
and (3) PI3K activation in otherwise nonmalignant cells permit-
ted the cells to grow in a malignant fashion in established
tumors. Thus, while cancers may become “addicted” to the
initiating oncogene (Giuriato et al., 2004), our experiments sug-
gest that the full might of oncogenes is much more important
to initiate tumors, and that only residual activities are essential,
at least in the case of Ras, to maintain tumor growth.
Why cancer cells can lose their dependency on oncogenic
Ras still remains to be resolved, but we speculate that, once a
tumor microenvironment is established, tumor vasculature or
stromal cells supply paracrine factors that activate Ras effector
pathways (Mueller and Fusenig, 2004). Additionally, we demon-
strate that, in the absence of oncogenic Ras, the MAPK and
RalGEF pathways become activated in tumor cells indepen-
dently of p110-CAAX expression once a tumor is established,
and that the cells depended upon these pathways for contin-
ued tumor growth. In fact, an established tumor (microenviron-
ment) even fostered the growth of nonmalignant cells, provided
the crucial PI3K/AKT pathway was activated. Perhaps, then,390similar premalignant cells generated during tumor evolution in
human cancers capitalize on the tumor microenvironment and
similarly grow in a parasitic fashion. Hence, a reduction in the
dependency for oncogenic signals as tumors progress could
lead to the expansion of cells with different levels of malig-
nancy, possibly accounting for some of the known hetero-
geneity of the malignant fraction of solid tumors.
Lastly, the discovery that PI3K activation was critical during
tumor maintenance highlights the importance of this pathway
as an anticancer target. We further distilled this pathway to
activation of AKT, consistent with the observation that this
pathway is commonly activated in human cancers. Importantly,
these observations were extended to human cancer cell lines,
suggesting that the importance of this pathway in experimental
systems of tumor maintenance may apply to actual human
cancers. Since cancers are treated at the tumor maintenance
stage, targeting this aspect of Ras oncogenesis may hold
promise as an approach to the management of Ras-driven hu-
man cancers.
Experimental procedures
Cell lines and plasmids
Primary HEK cells (kind gifts of Silvia Bacchetti) stably expressing the early
region of SV40 (encoding large T-Ag and small t-Ag) and the hTERT catalytic
subunit of telomerase, CAPAN-1 cells (Brummelkamp et al., 2002), or
SW480 cells (Ikehara et al., 2005) were stably infected to generate poly-
clonal populations as previously described (Hamad et al., 2002) with the
indicated retrovirus(es) derived from pBabe, pBabePuro, pBabeZeo, or
pBabeBlast with no insert or by subcloning into these vectors cDNAs en-
coding H-RasG12V, H-RasG12V,E37G, H-RasG12V,Y40C, H-RasG12V,T35S, p110-
CAAX, Rlf-CAAX, Raf22W (Hamad et al., 2002), ER:H-RasG12V (a kind gift
of Paul Khavari), myr-AKT-HA (Kulik et al., 1997), HA-RacQ61L (a kind gift
from Channing Der), PTEN (subcloned without HA tag from pCDNA3-PTEN-
HA; a kind gift of Chris Kontos), FLAG-MEKDN:ER (the MEK1 cDNA derived
from pEN-MEK1 [ATCC] was mutated by site-directed mutagenesis from
K97 to M [Mansour et al., 1994] and cloned in frame with a N-terminal FLAG
epitope tag by PCR upstream and in frame with the ER domain derived
from the aforementioned ER:H-RasG12V cDNA), PTEN:ER (generated by
cloning the aforementioned PTEN cDNA in frame upstream of the afore-
mentioned ER sequence), LacZ (subcloned from pCMV-β-Gal [Clontech]),
or siRNA-resistant K-RasG12V (in which the K-RasG12V cDNA, a kind gift of
Channing Der, was engineered by site-directed mutagenesis to contain the
silent mutation changes T36GGC to AGGA). For shRNA experiments, the
same cell lines were stably infected with the indicated retroviruses derived
from pSUPER-RETRO-PURO (Oligoengine) containing the shRNA PTEN
sequence CCCAGTCAGAGGCGCTATGTG or the scrambled derivative
CCAAGCCAGAGACGTTACGTA, or pSUPER-RETRO-GFP/NEO containing
K-RasG12V-specific shRNA (Brummelkamp et al., 2002). To achieve induc-
ible shRNA expression, cells were coinfected with pCMVneo (Bender et al.,
1987) encoding the TET repressor derived from pcDNA6-TR (Invitrogen) and
pSUPER-RETRO-PURO-TETO, engineered from pSUPER-RETRO-PURO
(Brummelkamp et al., 2002) to contain the TET operator (downstream of the
H1 promoter) and either no insert, shRNA specific for the G12V version of
K-Ras (Brummelkamp et al., 2002), or RalA shRNA (Lim et al., 2005).
Tumors and cell culture
SCID/beige mice were given seven daily intraperitoneal injections of 1 mg
4-OHT dissolved in 0.1 ml of peanut oil (Sigma) or, when indicated, peanut
oil alone, akin to methods previously described (Pelengaris et al., 2002),
then injected subcutaneously in the flanks with 107 TtH cells expressing
4-OHT ER:RasG12V, followed by daily injections of 4-OHT until (unless other-
wise specified) tumors reached a diameter of 0.7 cm. In some cases,
4-OHT treatments were supplemented by implanting subcutaneously a pel-
let containing 10 mg of 4-OHT. In the case of CAPAN-1 and SW480 cells
containing dox-inducible K-RasG12V shRNA or RasG12V-TtH cells containing
dox-inducible RalA shRNA, or 4-OHT-inducible MEKDN:ER or PTEN:ER,CANCER CELL : NOVEMBER 2005
A R T I C L Emice were supplied with water containing 1 mg/ml of dox hydrochloride
(Sigma) or injected with 4-OHT as above after tumors reached a diameter
of 0.7 cm (unless otherwise specified). Four or more mice were used per
treatment group in all experiments except when noted.
H&E staining, Ki67 immunohistochemistry (α-Ki67 antibody; Vector
Laboratories), and the TUNEL assay (Apoptag+ Peroxidase in situ Detection
Kit; Chemicon International) were performed on the indicated tumor sec-
tions using standard assays. For mixing experiments, 9 × 106 RasG12V-TtH
cells were mixed with 9 × 106 TtH cells expressing LacZ and p110-CAAX,
Raf22W, Rlf-CAAX, or no transgene (vector) and similarly injected into the
flanks of four mice. Once tumors were established, two tumors were treated
with X-gal using standard protocols to identify LacZ-positive cells. The two
other tumors were established in culture under G418 selection, the resulting
cell culture was stained with X-gal, and strongly positive blue cells were
counted.
In cases where tumor-derived cells were retested for tumor growth, tu-
mors were established in culture under puromycin selection to enrich for
TtH cells, except in the case of mixing experiments, in which cells were
selected under G418. The latter cells were also subjected to another round
of puromycin selection to specifically select LacZ + p110-CAAX TtH cells.
Cells were injected and assayed for tumor growth as described above. Ex-
perimental procedures involving mice were reviewed and approved by the
Duke University Institutional Animal Care and Use Committee.
Molecular analysis
The described Ras proteins, Raf22W, myr-AKT-HA or HA-Rlf-CAAX or HA-
RacQ61L, PTEN or PTEN:ER, actin, endogenous and ectopic K-Ras, FLAG-
MEKDN:ER, and RalA were detected by standard immunoblot analysis using
the primary antibodies α-Pan-Ras (Oncogene), α-Raf-1 (Santa Cruz), α-HA
(Roche), α-PTEN (Cell Signaling Technology), α-actin (Santa Cruz), α-K-Ras
(Santa Cruz), α-FLAG (Sigma), and α-RalA (Transduction Laboratories), re-
spectively. p110-CAAX mRNA was detected by reverse transcription PCR
amplification, as previously described (Hamad et al., 2002). MAPK, PI3K,
and RalA pathway activation was determined by culturing cells in 0.5% fetal
bovine serum for 48 hr in the presence or absence of 1 M 4-OHT (Sigma).
Derived cell lysates were immunoblotted as previously described (Hamad
et al., 2002) to detect AKT or the activated S473 phosphorylated form, or
ERK1/2 or the activated Thr202/Tyr204 phosphorylated forms, using the
primary antibodies α-Akt, α-phospho(Ser 473)-Akt (Cell Signaling Technol-
ogy), K-23 α-ERK1/2 (Santa Cruz), and E10 α-phospho(Thr202/Tyr204)-p42/
44 MAPK (Cell Signaling Technology), respectively, or to detect Ral-GTP, RalA
captured with bacterially expressed GST-RalBD of RalBP1 followed by im-
munoblot analysis with the aforementioned RalA antibody, respectively, as
previously described (Wolthuis et al., 1998).
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